U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07047521) titled 'A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults' on June 24.
Brief Summary: Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. The TDV in current formulation has been approved by health authorities in many countries around the world. The main aim of the study is to confirm that the TDV new formulation induces the similar immune response as approved TDV.
Healthy adults who live in an area in which dengue fever does not occur will receive 2 TDV vaccinations 3-months apart with either the new or the current TDV. B...